Which startup will cure hair loss?

What would a real hair-loss cure actually do?

A real hair-loss cure would bring back visible hair after a short treatment and keep it growing once the treatment ends.

That definition removes most products from the race. Minoxidil can stimulate growth, finasteride can slow further loss, and transplants can move existing follicles. All three help many people, yet none restores the scalp’s own ability to replace lost follicles permanently. Separating true cures from products that only slow or manage hair loss is the first cut we make in our market report about biotech.

There are two realistic versions of a future cure. The first would wake up miniaturized or dormant follicles and make them produce thick hair again for years. The second would create replacement follicles where the original ones have been destroyed. The first route looks clinically reachable. The second remains much further away.

For this article, we call it a cure when it restores hair that current medicines cannot recover and avoids another daily treatment for life. A cure could still work only for certain people or certain types of alopecia.

Are hair-loss startups even trying to cure the same disease?

Hair-loss startups are chasing several different diseases, so one company is unlikely to cure every kind of baldness.

Most companies in this race are working on androgenetic alopecia, the common form of male and female pattern hair loss. Genetically vulnerable follicles gradually shrink. The hairs become thinner, grow for less time and may eventually become almost invisible.

Alopecia areata works differently. The immune system attacks follicles and can cause sudden bald patches or complete hair loss. Immune-blocking JAK medicines have transformed treatment for some patients, although relapses remain common and dermatologists still do not describe the disease as cured.

Scarring alopecias create an even harder problem because inflammation can destroy the follicle itself. A drug that wakes up a sleeping follicle may help pattern baldness while offering little to someone whose follicles have disappeared.

Pelage, Amplifica, Absci, Hope Medicine, Eirion and Veradermics therefore belong mainly in the pattern-hair-loss race. dNovo was one of the few startups aiming at the deeper problem of replacing follicular cells.

Why is pattern baldness still so hard to reverse?

Pattern baldness is hard to reverse because every follicle is a tiny living organ with several systems working together.

A healthy follicle coordinates stem cells, dermal papilla cells, blood vessels, connective tissue, hormones and several growth pathways. Restarting one part may produce a few extra hairs. Rebuilding natural density requires the whole system to work together for repeated growth cycles.

Researchers once hoped that balding scalps mainly contained sleeping stem cells waiting for the right trigger. That idea still looks useful, but single-cell studies show a messier picture. Balding follicles can also lose progenitor cells, receive weaker growth instructions and develop changes in the tissue around them.

Human biology adds another difficulty. Mouse hair grows quickly and synchronously, which makes dramatic regrowth easier to show. Human scalp hairs grow over years, react differently across the hairline and crown, and must emerge with the right thickness, angle, color and direction. Many treatments that look spectacular on mice never clear that bar.

The field is more credible now because several new mechanisms are in controlled human studies. Trials are testing stem-cell activation, prolactin-receptor blockade, injectable growth molecules and improved oral minoxidil. Two of them, PP405 and extended-release minoxidil, are now in studies of 500 or more people.

Which company is closest to changing hair-loss treatment today?

Veradermics is closest to a major new product, while Pelage is closest to a treatment that could feel like a cure.

Veradermics shares the most advanced stage with Cosmo, below. Its extended-release oral minoxidil has now produced two positive placebo-controlled trials in more than 1,000 men. A larger randomized trial in 556 women is fully enrolled, with results expected in the first half of 2027. Two positive placebo-controlled trials in one indication are the type of signal we log every quarter in our report on biotech.

Cosmo Pharmaceuticals, a listed Swiss company, is the other near-market name. Its topical anti-androgen clascoterone completed two Phase 3 trials in 1,465 patients, and Cosmo said in April 2026 that it plans to file with the FDA in early 2027. Like Veradermics, it treats hair loss rather than reversing it.

Pelage is a step behind in stage and trying something more ambitious. PP405 aims to restart dormant follicular stem cells, and its Phase 2/3 AWAKEN trial began dosing in October 2026.

Amplifica has new money but no new data. Absci is waiting on its first human hair counts. Hope Medicine still has not released its mid-stage result. Eirion has a fast early readout from only 24 people. dNovo appears to have stopped.

Company	Where it stands now	What it could deliver	Our take
Veradermics	Two positive late-stage trials in men; female trial fully enrolled	A stronger oral treatment	Closest to market
Cosmo Pharmaceuticals	Two Phase 3 trials completed; FDA filing planned for early 2027	A new topical anti-androgen	Near market, not a cure
Pelage Pharmaceuticals	Phase 2/3 trial of about 600 men started in October 2026	Dormant follicles produce thick hair again	Best cure-like startup
Amplifica	First human study completed; $26 million Series B in August 2026	Months of growth after a short injection cycle	Funded outsider, thin data
Absci	Phase 1/2a multiple dosing in patients; interim hair data due	Infrequent antibody injections restart growth	Serious, still early
Hope Medicine	Phase 2 completed	Prolactin-receptor blockade works in humans	Impossible to rank without results
Eirion Therapeutics	Small first-in-human study	Fast topical regrowth	Interesting, weak proof
dNovo	Listed as inactive; no human trial	Replacement follicles for irreversible baldness	Effectively out of the race

Does Veradermics’ second Phase 3 win change the hair-loss race?

It changes the treatment race, not the cure race. Veradermics will very likely bring the biggest treatment upgrade in decades, but it will not cure pattern baldness.

Its drug, VDPHL01, is an extended-release version of minoxidil. The new formulation keeps the drug circulating more steadily and may expose follicles to an effective dose without the sharp blood-level peak of ordinary oral minoxidil.

The two male trials now agree. In Study 302, reported in April 2026, 519 men on the once-daily and twice-daily doses gained 30.3 and 33.0 non-vellus hairs, meaning thicker visible hairs, per square centimeter after six months. Placebo added 7.3. In Study 304, reported on 19 October 2026 in 536 men, the gains were 28.6 and 36.4 hairs, against 6.6 on placebo.

Around 79% of once-daily patients and 85% to 86% of twice-daily patients reported visible improvement in both studies, against about 35% on placebo. Two consistent trials of this size are the kind of package a drug application is built on, although the company has not given a filing date.

There is a cost. In Study 304, unwanted body-hair growth affected 9.0% of patients on the twice-daily dose, and leg swelling 4.5%. The company reported no treatment-related serious events and no cardiac events of special interest.

Veradermics also has the money to launch. It held $819.9 million in cash and securities at the end of June 2026 after raising about $472 million in May, which it says funds operations into 2030. As a public company it is out of the literal startup race, but it sets the bar every private contender must beat.

VDPHL01 remains a better delivery system for an old growth stimulant. Patients would probably need to keep taking it, and the genetic process that shrinks vulnerable follicles would continue in the background.

Is Pelage Pharmaceuticals the startup to beat?

Yes. Pelage is currently the strongest private startup in the race to produce cure-like hair regrowth, and it is the only one in a large controlled trial.

PP405 changes the metabolism of hair-follicle stem cells. The goal is to push dormant cells back into an active state so the follicle can make a thick terminal hair again. That approach goes closer to the source of the problem than another stimulant or hormone blocker.

The product also looks practical to develop. The topical gel showed no detectable drug in the bloodstream in its Phase 2a study.

In October 2026, after what it called a positive end-of-Phase 2 meeting with the FDA, Pelage dosed the first patient in AWAKEN. The trial plans to enroll about 600 men with Norwood-Hamilton type IV or V loss in the U.S. and Canada, over 12 months. It will measure visible hair counts, patient-reported results and signs of follicular reactivation. Pelage also plans a Phase 2 trial in women by the end of 2026.

The money is there. Pelage raised $120 million in its October 2025 Series B, enough to carry a trial of this size.

The lead is still narrow. AWAKEN enrolls precisely the men with more advanced loss who drove the best Phase 2a result, which is sensible but means the broad effect is still unproven. Results are unlikely before 2027. No other private company has shown the same mix of a new mechanism, human results and a running late-stage trial.

Does PP405’s human evidence really hold up?

PP405’s trial is good enough to take seriously and far too small to call a cure.

The randomized Phase 2a study enrolled 78 men and women. Participants used PP405 or placebo for four weeks and were followed for another eight.

Among men with more advanced hair loss, 31% of treated participants achieved more than a 20% rise in hair density by week eight. None of the placebo participants in that group crossed the same threshold.

For an early study, the gap between the two groups is impressive. It also means that 69% of the highlighted treated group failed to reach the company’s chosen response level. Pelage has not publicly provided enough detail to calculate the average cosmetic benefit across the whole trial or to know how large that subgroup was.

The most interesting finding came from mapped follicular units, the small natural groups in which scalp hairs grow. Pelage reported thick terminal hairs growing from units that had produced no visible hair before treatment.

That supports follicle reactivation, although a severely miniaturized hair can be almost invisible. The trial cannot yet prove that a dead follicle came back to life.

AWAKEN now has to answer three questions: how many people respond, how visible the change is, and how long the new hair survives. Its main measure, non-vellus hair count, is the same one Veradermics used, so the two will be easy to compare. Calling PP405 a cure already would be premature.

Could Amplifica beat Pelage with a few injections?

Amplifica could beat Pelage on convenience and durability, although the company has disclosed too little data to take the lead.

AMP-303 is injected directly into the scalp. In its first human study, each participant received the drug on one side of the frontal-temporal area and placebo on the other. That within-person design removes much of the noise caused by genetics, age and baseline hair density.

Amplifica said its responder rate was statistically significant: some participants gained more than 15% additional non-vellus hairs over placebo after 60 days. The advantage remained above 10% after 150 days, and the company also saw fine hairs becoming thicker terminal hairs.

Five months of measurable benefit after one treatment cycle would be a real advance. Many people tolerate occasional injections more easily than a daily pill or topical gel, especially when the result continues after the appointment.

In August 2026, Amplifica closed a $26 million Series B led by Tasso Partners, with Eli Lilly among the investors. That is more than twice its 2022 Series A of $11.8 million, and Lilly’s presence is a signal. It is still about a fifth of Pelage’s last round.

But Amplifica leaves out the numbers we need. It has never disclosed the total sample size, the exact response rate, the average hair-count difference or the identity of AMP-303, and the funding announcement named no next trial. Pelage remains ahead until Amplifica publishes a fuller dataset or starts a clearly defined study. Whether backers fund a startup before its next trial is named says a lot about what investors back, and we trace that in our report on biotech.

Has Hope Medicine gone quiet for a bad reason?

The silence around Hope Medicine’s HMI-115 is now a serious weakness in the program.

HMI-115 blocks the prolactin receptor, a new target in hair biology. An early open-label study in 12 men found an average gain of about 14 non-vellus hairs per square centimeter after 24 weeks. Four women also took part, but that tiny uncontrolled study could only justify a larger test.

Hope Medicine then completed a randomized Phase 2 trial in 192 men. Few novel hair-loss drugs have reached a controlled study that large, so the trial should have given a clear answer about the target. Why some startups stall after a mid-stage trial is a question we study in our report covering the biotech market.

ClinicalTrials.gov lists the study as completed, yet we found no public efficacy result. Successful biotech companies usually announce a clear mid-stage win, especially in a consumer market this large.

Delays can come from analysis, publication plans or regulatory discussions, so silence alone cannot prove failure. Hope Medicine has also put visible effort into using HMI-115 for endometriosis pain. Still, the silence lowers the hair program’s rank. Quite a lot, at this point.

Hope Medicine may still surprise the field. Until it publishes the trial, it belongs below companies that have shown their data.

Is Absci becoming a real threat in hair loss?

Absci is the challenger most likely to move the ranking soon, because its first human hair-growth data are due.

ABS-201 is another antibody against the prolactin receptor, designed with Absci’s AI drug platform. Its animal results attracted attention because treated mice and balding macaques grew substantial hair, but animal regrowth has fooled this field many times.

In June 2026, Absci reported that the drug was well tolerated across four blinded single-dose groups of 32 healthy adults, with no serious adverse events. It estimated a half-life of at least 65 days, which could allow two or three injections over six months.

The trial has moved into multiple dosing in people with androgenetic alopecia, with hair assessed at 13 and 26 weeks. Absci said in August 2026 that interim proof-of-concept data are expected in the second half of 2026 and full data in early 2027. Until those numbers arrive, the half-life shows dosing could be convenient, not that the treatment works.

Funding will not slow the program. A $100 million offering in June 2026 included a $40 million strategic investment from Eli Lilly, and Absci reported $201.1 million in cash at the end of June, enough, it says, to run into the second half of 2028.

Absci is publicly traded, which keeps it out of the literal startup answer.

Is Eirion’s five-week result believable?

Eirion’s ET-02 result is worth following, but five weeks and 24 participants provide flimsy proof of lasting regrowth.

The first-in-human study tested a topical treatment in three groups of eight people: vehicle, a low dose and a higher dose. Eirion reported that the high dose produced six times the non-vellus hair increase of its combined comparison group after five weeks, along with thicker hair shafts.

Five weeks sounds impressive, although human scalp hair grows slowly. That window is unusually short for judging whether new hairs become visible, survive and complete a normal cycle.

The comparison was also unusually generous to Eirion. It combined the placebo group with the ineffective low-dose group, then compared the result with historical minoxidil data from another trial. A direct head-to-head study would be much more convincing.

ET-02 may have found a fast stem-cell pathway. We found no public report of a larger trial, so for now the result supports a six-month study and little more.

Is dNovo still in the race to grow new hair follicles?

Probably not. dNovo aimed at the hardest prize, creating replacement hair-producing cells, but Y Combinator’s company directory now lists it as inactive, with four staff and no open roles.

The company reprogrammed cells from skin, blood or fat into hair stem cells and dermal papilla cells, which help tell a follicle when to grow. Those cells would then be placed into the scalp to form new hair-producing structures.

In theory, this could help smooth bald areas and some forms of scarring alopecia that follicle-activating drugs cannot reach.

dNovo transplanted reprogrammed human cells into hair-deficient mice. Hair appeared after three weeks and became clearly visible during the second month. The experiment showed that the cells can help make hair in a mouse.

It said very little about whether thousands of new human follicles can be created safely, placed at natural angles and kept cycling for years.

We could find no human trial and no public milestone after 2021. Pelage’s $120 million round alone was more than 40 times dNovo’s disclosed $2.7 million seed round.

Cell therapy requires custom manufacturing, quality control and a surgical delivery method, so the capital gap was a practical obstacle.

Stemson Therapeutics showed how punishing this route can be. Stemson also developed lab-made follicular structures and shut down before human testing after struggling to finance the program. dNovo now looks like a second example.

Can any startup regrow hair on a smooth bald scalp?

No startup has shown that it can restore dense, natural hair across a long-bald human scalp.

Most clinical candidates still need a living follicle. They may restart a dormant unit, thicken a miniaturized hair or extend the growth phase. A scalp can look bare while retaining many tiny follicles, so advanced-looking baldness does not always mean every follicle has vanished. Different stages of baldness mean different customers with different problems they would pay to solve, which we describe in our market report about biotech.

Once the follicle structure is destroyed, the problem changes. Drugs such as PP405, AMP-303 and prolactin-receptor antibodies have nothing obvious to activate. A cell-replacement approach or a transplant becomes necessary.

The future market will probably split in two. People with early or moderate thinning may receive a regenerative drug before too much structure is lost. People with smooth, long-established bald areas may still need surgery or lab-grown follicles.

The first company called a hair-loss cure will probably help the first group. A universal cure that rebuilds a fully bald scalp remains a separate and much harder invention, and no well-funded startup is visibly working on it in humans.

Will women get the same hair-loss breakthrough as men?

Women are included in more programs, but the strongest efficacy data still come from men.

Pelage enrolled men and women in its Phase 2a trial, yet AWAKEN is men only. The company plans a separate Phase 2 study in women by the end of 2026. Absci’s program includes both sexes, while Amplifica’s first study enrolled only younger men.

Veradermics has moved fastest in women. Its 28-person open-label study found average gains of roughly 23 non-vellus hairs per square centimeter after six months. Almost nine in ten participants reported better coverage, and the company reported no treatment-related serious or cardiac events.

That study lacked a placebo group. The randomized trial in 556 women completed enrollment in August 2026 and should report in the first half of 2027. It will decide how persuasive the female numbers really are.

Female pattern hair loss is also less neatly explained by androgen biology than male pattern baldness. That uncertainty could favor treatments that act directly on follicle metabolism or the hair cycle instead of relying on hormone suppression.

Any company claiming a broad breakthrough will need convincing female data. Women have fewer approved oral options, and a safe non-hormonal treatment could fill a larger gap for them than for men.

Can the new treatments keep working after patients stop?

No startup has proved permanent regrowth after treatment ends, and that remains the biggest hole in every cure claim.

Pelage measured its highlighted response four weeks after a four-week course. That shows the effect survived briefly beyond dosing. It cannot tell us whether the same hairs remain after six months or several growth cycles. AWAKEN runs for 12 months, but under continued or blinded treatment, not as an off-drug test.

Amplifica has the strongest early durability result. Its one treatment cycle still showed an advantage over placebo after 150 days.

Absci may require only two or three injections over six months because the antibody stays in the body for a long time, although that would still be continuous drug action.

A convincing cure trial would stop treatment and follow patients long enough to see whether the same follicles keep producing thick hair. The microscopic counts should also match standardized photos, patient reports and ratings from doctors who do not know which treatment each person received.

Candidate	Best durability data	What remains unanswered
PP405	Growth measured four weeks after dosing ended	Whether the gain survives for a year
AMP-303	Benefit reported 150 days after one cycle	Exact response rate and longer follow-up
ABS-201	Half-life of at least 65 days	Whether human hair grows at all
HMI-115	Six months of scheduled injections	Results and off-treatment persistence
VDPHL01	Six months of continuous daily use in two trials	What happens after patients stop
dNovo	Hair growth in mice after cell placement	Whether the program continues at all

Which startup will cure hair loss?

Pelage Pharmaceuticals is the best answer as of now, although the first PP405 product would more likely be a long-lasting regenerative treatment than a permanent universal cure.

Pelage has the best mix of human results, a regenerative idea and a product being tested at scale. Its 600-man Phase 2/3 trial began dosing in October 2026, and no other private contender has reached a late-stage study.

Absci is the outsider most likely to move first, because its interim human hair data are due. Amplifica has fresh money and Lilly’s backing, but it still needs to reveal the size and full outcome of its study.

Veradermics will likely reach patients long before any cure-like candidate and may become the most successful product in the group, now that two large trials in men agree. Its drug improves minoxidil rather than rebuilding the follicle, so it belongs in the treatment race more than the cure race.

Cell replacement remains the boldest long-term route, but it has lost momentum. With Stemson closed and dNovo listed as inactive, no startup is visibly bringing lab-made follicles toward people.

So our answer is Pelage. It is currently the startup most likely to create the first hair-loss treatment that patients casually call a cure, probably through meaningful regrowth after a course of treatment and occasional retreatment.

A permanent cure for a fully bald scalp will arrive later, if at all, from cell replacement, and no startup is close to proving it now.